STXS Stock Recent News

ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum “Homi” Shamir to its Board of Directors.

ST. LOUIS, May 29, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announces the successful treatment of the first heart rhythm patients by Penn Presbyterian Medical Center (PPMC) utilizing the advanced Genesis Robotic Magnetic Navigation System. PPMC, part of the University of Pennsylvania Health System, renowned for advanced clinical research, innovation, and compassionate patient care, stands at the forefront as the first in the Northeast United States to offer the Genesis System.

Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.

Stereotaxis (STXS) announces the completion of treatment of first heart rhythm patients with its Genesis Robotic Magnetic Navigation system in Southern Italy.

ST. LOUIS, May 24, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received CE Mark recertification under the European Union's new Medical Device Regulation (MDR) regulatory framework. The recertification under MDR covers all Stereotaxis devices currently available in Europe.

Stereotaxis made a strategic acquisition of catheter company Access Point Technologies, which is expected to contribute $5 million in sales in the first 12 months after the acquisition. Access Point will help Stereotaxis release a robotically navigated guide catheter and a robotically navigated mapping catheter. Stereotaxis is working with regulators to get MAGiC approved. The CE Mark should be coming late this summer. PMA approval should come at year-end.

Stereotaxis presents innovative proposal leveraging advanced robotic technology and telerobotic presence to sustainably offer high-quality cardiac ablati

Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.

Stereotaxis, Inc. (NYSE:STXS ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason Wittes - ROTH MKM Adam Maeder - Piper Sandler Joshua Jennings - TD Cowen Operator Good afternoon. Thank you for joining us for Stereotaxis' First Quarter 2024 Earnings Conference Call.

ST. LOUIS, April 22, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 first quarter on Monday, May 13, 2024 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m.